WallStSmart
ENGN

enGene Holdings Inc. Common Stock

NASDAQ: ENGN · HEALTHCARE · BIOTECHNOLOGY

$1.54
-2.25% today

Updated 2026-06-02

Market cap
$115.56M
P/E ratio
P/S ratio
EPS (TTM)
$-2.18
Dividend yield
52W range
$1 – $12
Volume
1.8M

enGene Holdings Inc. Common Stock (ENGN) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item202020212022202320242025
Operating cash flow$-13.06M$-15.98M$-17.59M$-24.74M$-48.28M$-99.24M
Capital expenditures$192000.00$248000.00$153000.00$318000.00$925000.00$1.49M
Depreciation$259000.00$272000.00$238000.00$175000.00$91000.00$-2.56M
Stock-based comp$150000.00$435000.00$116000.00$3.45M$5.32M$9.65M
Free cash flow$-13.25M$-16.23M$-17.75M$-25.06M$-49.21M$-100.72M
Investing cash flow$-192000.00$-247000.00$-153000.00$-318000.00$-125.95M$-25.14M
Financing cash flow$12.85M$22.52M$27.97M$86.15M$265.72M$1.52M
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does ENGN generate?

ENGN produced $-100.72M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ENGN's balance sheet healthy?

ENGN holds $50.15M in cash and equivalents against $15.32M in long-term debt, on $167.71M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.